BRCA2 and pachyonychia congenita: The risk of PC is up to five-fold higher in BRCA2 variant carriers than in general population and has been reported to be more aggressive (frequently with Gleason scores ≥ 8) and associated with worse survival compared to BRCA wild-type cancers (Ibrahim et al. 2018).